

# Sido Muncul Tbk (SIDO IJ)

## Tingginya Inflasi Sebabkan Penurunan Permintaan

Baik penjualan maupun laba bersih SIDO pada 2Q22 kompak mengalami penurunan masing-masing 15% YoY dan 35% YoY. Kenaikan inflasi bahan pangan yang mendorong konsumen memilih lebih fokus penuhi kebutuhan pokok menjadi penyebab menurunnya permintaan produk SIDO. Adapun, untuk mengimbangi penurunan permintaan pada pasar domestik, SIDO berupaya terus melakukan ekspansi untuk menopang bisnis internasionalnya.

### Rendahnya Permintaan Menurunkan Kinerja 2Q22

- Sepanjang 6M22, SIDO membukukan penjualan sebesar Rp1,6 triliun atau turun 3% YoY.
- Penurunan ini disebabkan oleh rendahnya permintaan baik untuk segmen Herbal dan F&B di pasar domestik. Sementara, untuk segmen Farmasi dengan adanya permintaan yang stabil, mampu tumbuh sebesar 17% YoY.
- Secara kuartalan, penjualan 2Q22 tercatat Rp731,6 miliar (-15% YoY) dengan segmen Jamu Herbal dan Suplemen mencatatkan penurunan terbesar (-17% YoY) menjadi Rp459,7 miliar.
- Laba kotor 2Q22 tercatat lebih rendah menjadi Rp372,7 miliar (-23% YoY). Laba operasi turun 34% YoY pada 2Q22 menjadi Rp191,5 miliar sejalan dengan penurunan OPEX ke Rp187,4 miliar (-3% YoY).
- Ke depannya, SIDO akan melakukan efisiensi pada OPEXnya untuk mempertahankan harga jual dan menghindari penurunan daya beli. Adapun, laba bersih 2Q22 juga tercatat turun 35% YoY ke Rp150,6 miliar (vs 2Q21: Rp233,0 miliar).
- Margin profitabilitas tercatat lebih rendah pada 2Q22, disebabkan oleh volume penjualan yang turun. GPM, OPM, dan NPM masing-masing tercatat sebesar 51%, 26%, dan 21% (vs 2Q21: GPM 56%, OPM 34%, dan NPM 27%).

### Semua Segmen Kompak Mengalami Penurunan

- Menurunnya permintaan produk SIDO diakibatkan oleh tingginya inflasi bahan pangan, sehingga konsumen lebih memilih untuk fokus memenuhi kebutuhan pokok.
- Segmen Herbal & Supplement per 1H22 mencatatkan margin yang stabil yaitu 66%-67% di tengah melambatnya permintaan jamu khususnya pada kategori Cold Symptom.
- SIDO pun memproyeksikan bahwa margin untuk segmen F&B ke depan akan meningkat dikarenakan sebagian besar harga untuk produk-produk utamanya telah disesuaikan.
- Menurunnya kinerja segmen F&B didorong oleh melambatnya permintaan produk Kuku Bima Energi dan Vit.C. Adapun, produk Kuku Bima Energi (kontribusi terhadap penjualan sebesar 16%) mencatatkan penjualan ekspor yang lebih tinggi di Nigeria dan Malaysia.
- Dari segmen Farmasi, permintaan tercatat stabil pada 1H22, didukung oleh produk terkait Covid19, antara lain parasetamol, obat batuk sirup, dll.
- Untuk bisnis internasional (kontribusi 6% terhadap penjualan), SIDO memanfaatkan lini bisnis untuk mengimbangi penurunan yang terjadi di pasar domestik. Per 1H22, bisnis internasional tumbuh 80% YoY dengan mencatatkan negara ekspor terbaru yaitu Senegal dan Togo.
- Adapun, untuk 3Q22 SIDO berencana untuk melakukan ekspansi ke negara Ghana dan Kamerun, sementara untuk 4Q22 ke negara China, Kenya, dan Vietnam.

### Rekomendasi BUY dengan TP Rp900

- Kami memberikan rekomendasi Buy untuk SIDO dengan target price Rp900/saham. TP ini mengimplikasikan P/E sebesar 17,4x atau -1 STD dengan potensi kenaikan sebesar 18,4%. Adapun risikonya yaitu kenaikan harga bahan baku, daya beli konsumen, dan penurunan permintaan produk.

### PT Sido Muncul Tbk | Summary (IDR Bn)

	2021A	2022F	2023F	2024F
Sales	4,021	4,530	4,988	5,589
Growth	20.6%	12.7%	10.1%	12.1%
Net Profit	1,261	1,411	1,586	1,816
Growth	35.0%	11.9%	12.4%	14.5%
EPS (IDR)	38	47	53	61
P/E	22.8x	19.1x	17.0x	14.9x
P/BV	7.5x	7.1x	6.5x	6.0x
EV/EBITDA	14.8x	14.0x	12.3x	10.7x
ROE	36.3%	37.1%	38.4%	40.6%
ROA	31.0%	30.7%	32.1%	34.0%
Dividend Yield	3.9%	4.2%	4.8%	5.4%

Source: Company Data, Bloomberg, NHKSI Research  
Please consider the rating criteria & important disclaimer

## BUY

Price Target (IDR)	900
Consensus Price (IDR)	984
TP to Consensus Price	-8.5%
Potential Upside	18.4%

### Shares data

Last Price (IDR)	760
Price Date as of	August 5, 2022
52 wk Range (Hi/Lo)	1,070/740
Free Float (%)	22.3
Outstanding sh.(mn)	30,000
Market Cap (IDR bn)	22,800
Market Cap (USD mn)	1,526
Avg. Trd Vol - 3M (mn)	32.30
Avg. Trd Val - 3M (bn)	31.5
Foreign Ownership (%)	9.8

### Healthcare

#### Pharmaceutical

Bloomberg	SIDO IJ
Reuters	SIDO.JK

### Share Price Performance



	YTD	1M	3M	12M
Abs. Ret.	-12.6%	-22.1%	-19.1%	-2.6%
Rel. Ret.	-18.9%	-27.7%	-21.7%	-21.1%


### Cindy Alicia Ramadhania

(021) 5088 9129

cindy.alicia@nhsec.co.id


# Performance Highlights

## SIDO's Revenue Breakdown (2Q22)




Source: Company Data, NHKSI Research

## SIDO's Revenue by Segments (IDR Bn)




Source: Company Data, NHKSI Research

## SIDO's Revenue Growth



Source: Company Data, NHKSI Research

## SIDO's Margin Ratio



Source: Company Data, NHKSI Research

## Forward P/E Band (Last 3 Years)



Source: Company Data, NHKSI Research

## Dynamic Forward P/E Band (Last 3 Years)



Source: Company Data, NHKSI Research

## Summary of Financials

INCOME STATEMENT					PROFITABILITY & STABILITY				
(IDR bn)	2021/12A	2022/12E	2023/12E	2024/12E		2021/12A	2022/12E	2023/12E	2024/12E
<b>Net Sales</b>	<b>4,021</b>	<b>4,530</b>	<b>4,988</b>	<b>5,589</b>	ROE	36.3%	37.1%	38.4%	40.6%
<i>Growth</i>	20.6%	12.7%	10.1%	12.1%	ROA	31.0%	30.7%	32.1%	34.0%
COGS	(1,735)	(2,023)	(2,233)	(2,497)	Inventory Turnover	4.5x	4.7x	4.7x	4.6x
<b>Gross Profit</b>	<b>2,286</b>	<b>2,507</b>	<b>2,755</b>	<b>3,092</b>	Receivable Turnover	6.1x	6.7x	6.7x	6.5x
<i>Gross Margin</i>	56.9%	55.3%	55.2%	55.3%	Payables Turnover	8.8x	8.6x	8.7x	8.7x
Operating Expenses	(705)	(784)	(922)	(993)	Dividend Yield	3.9%	4.2%	4.8%	5.4%
<b>EBIT</b>	<b>1,581</b>	<b>1,723</b>	<b>1,964</b>	<b>2,248</b>	Payout Ratio	89.5%	0.0%	0.0%	0.0%
<i>EBIT Margin</i>	39.3%	38.0%	39.4%	40.2%	DER	0.0x	0.0x	0.0x	0.0x
Depreciation	94	96	95	95	Net Gearing	0.0x	0.0x	0.0x	0.0x
<b>EBITDA</b>	<b>1,675</b>	<b>1,818</b>	<b>2,059</b>	<b>2,343</b>	Equity Ratio	85.3%	82.7%	83.7%	83.6%
<i>EBITDA Margin</i>	41.7%	40.1%	41.3%	41.9%	Debt Ratio	0.2%	0.0%	0.0%	0.0%
Interest Expenses	-	-	-	-	Financial Leverage	101.2%	96.5%	104.0%	99.2%
<b>EBT</b>	<b>1,613</b>	<b>1,751</b>	<b>2,011</b>	<b>2,293</b>	Current Ratio	4.1x	3.7x	4.0x	4.1x
Income Tax	(352)	(339)	(425)	(476)	Quick Ratio	3.3x	3.1x	3.4x	3.4x
Minority Interest	-	-	-	-	Par Value (IDR)	10	10	10	10
<b>Net Profit</b>	<b>1,261</b>	<b>1,411</b>	<b>1,586</b>	<b>1,816</b>	Total Shares (mn)	30,000	30,000	30,000	30,000
<i>Growth</i>	35.0%	11.9%	12.4%	14.5%	Share Price (IDR)	865	900	900	900
<i>Net Profit Margin</i>	31.4%	31.2%	31.8%	32.5%	Market Cap (IDR tn)	26.0	27.0	27.0	27.0
BALANCE SHEET					VALUATION INDEX				
(IDR bn)	2021/12A	2022/12E	2023/12E	2024/12E		2021/12A	2022/12E	2023/12E	2024/12E
Cash	1,082	1,604	1,727	1,918	Price /Earnings	22.8x	19.1x	17.0x	14.9x
Receivables	664	687	744	863	Price /Book Value	7.5x	7.1x	6.5x	6.0x
Inventories	455	413	475	539	PE/EPS Growth	0.7x	1.6x	1.4x	1.0x
<b>Total Current Assets</b>	<b>2,245</b>	<b>2,749</b>	<b>2,990</b>	<b>3,365</b>	EV/EBITDA	14.8x	14.0x	12.3x	10.7x
Net Fixed Assets	1,600	1,645	1,730	1,768	EV/EBIT	15.7x	14.7x	12.9x	11.2x
Other Non Current Assets	225	205	217	215	EV (IDR bn)	24,874	25,396	25,273	25,082
<b>Total Non Current Asset</b>	<b>1,824</b>	<b>1,849</b>	<b>1,946</b>	<b>1,984</b>	Sales CAGR (3-Yr)	9.0%	13.3%	13.9%	14.4%
<b>Total Assets</b>	<b>4,069</b>	<b>4,599</b>	<b>4,936</b>	<b>5,348</b>	Net Income CAGR (3-Yr)	20.5%	23.8%	20.5%	19.3%
Payables	189	281	258	287	Basic EPS (IDR)	38	47	53	61
ST Bank Loan	6	-	-	-	BVPS (IDR)	116	127	138	149
<b>Total Current Liabilities</b>	<b>543</b>	<b>745</b>	<b>748</b>	<b>822</b>	DPS (IDR)	34	37	43	49
LT Debt	2	-	-	-					
<b>Total Liabilities</b>	<b>598</b>	<b>796</b>	<b>804</b>	<b>875</b>	OWNERSHIP				
Capital Stock & APIC	2,149	2,152	2,152	2,152	<b>Shareholders</b>				%
Retained Earnings	1,323	1,652	1,980	2,321	PT HOTEL CANDI BARU				60.5
<b>Shareholders' Equity</b>	<b>3,471</b>	<b>3,803</b>	<b>4,133</b>	<b>4,473</b>	CONCORDANT INVESTMENTS LP				17.1
					Norges Bank				1.0
					BlackRock Inc				0.6
CASH FLOW STATEMENT					<b>By Geography</b>				%
(IDR bn)	2021/12A	2022/12E	2023/12E	2024/12E	Indonesia				90.2
Operating Cash Flow	1,199	1,405	1,567	1,801	Luxembourg				1.7
Investing Cash Flow	(124)	(198)	(156)	(141)	Norway				1.2
Financing Cash Flow	(1,025)	(686)	(1,289)	(1,469)	United States				1.2
<b>Net Changes in Cash</b>	<b>50</b>	<b>522</b>	<b>123</b>	<b>191</b>					

Source: Company Data, NHKSI Research

**NH Korindo Sekuritas Indonesia (NHKSI) Stock Ratings**

1. Based on a stock's forecasted absolute return over a period of 12 months from the date of publication.
2. Rating system based on a stock's potential upside from the date of publication
  - Buy : Greater than +15%
  - Overweight : +5% to 15%
  - Hold : -5% to +5%
  - Underweight : -5% to -15%
  - Sell : Less than -15%

**DISCLAIMER**

This document is strictly confidential and is being supplied to you solely for your information. The recipients of this report must make their own independent decisions regarding any securities or financial instruments mentioned herein. This document may not be quoted, reproduced, exhibited, redistributed, transmitted, edited, translated, or published, in whole or in part, for any purpose without notice. Any failure to comply with this restriction may constitute a violation of civil or criminal laws.

This report and any electronic access hereto are restricted and intended only for the clients and related entities of PT NH Korindo Sekuritas Indonesia. This report is only for information and recipient use. It is not reproduced, copied, or made available for others. Under no circumstances is it considered as a selling offer or solicitation of securities buying. Any recommendation contained herein may not be suitable for all investors. Although the information hereof is obtained from reliable sources, its accuracy and completeness cannot be guaranteed. PT NH Korindo Sekuritas Indonesia, its affiliated companies, employees, and agents are held harmless from any responsibility and liability for claims, proceedings, action, losses, expenses, damages, or costs filed against or suffered by any person as a result of acting pursuant to the contents hereof. Neither is PT NH Korindo Sekuritas Indonesia, its affiliated companies, employees, nor agents are liable for errors, omissions, misstatements, negligence, inaccuracy contained herein. All rights reserved by PT NH Korindo Sekuritas Indonesia.